Poractant Alfa: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Poractant Alfa. Educational only — not medical advice.

Labeled uses

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Source: FDA labeling via NIH DailyMed (set 99bef307…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.